Last reviewed · How we verify
NCT02518035
Use of Silicone Gel to Improve Retroauricular Scar in Microtia Patients
Phase 4 trial testing Silicone Gel in Microtia in 32 participants. Status unknown.
1 August 2018
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 July 2015 |
| Primary completion | 1 August 2018 |
| Estimated completion | 1 August 2018 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Silicone Gel
Conditions studied
Sponsor
Chang Gung Memorial Hospital
Who can join
Adults 9 to 20, any sex, with Microtia or Scar. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Scar width
Time frame: 6 months after surgery
6 months after surgery, the scar width will be measured
Sponsor's own description
Effort to reduce post-surgical scar is especially important for microtia patients. Even the scar lies posterior to ear auricle, but hypertrophic scar contracture may limit the ear auricle projection. If the scar is hypertrophic and conspicuous, this stigmata will accompanies the child for many years.The main objective aim of this study is to examine whether post-operative use of silicone gel can improve scar formation for microtia reconstruction scars.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02518035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Microtia
Currently open trials in the same condition.
- NCT07154667 — Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction · NA · recruiting
- NCT06394687 — The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule · NA · active not recruiting
- NCT05288790 — Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT · Phase 2 · recruiting
- NCT05929976 — InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort · recruiting
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02518035 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 6 August 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02518035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing